Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.08 Insider Own22.68% Shs Outstand255.92M Perf Week8.12%
Market Cap1.60B Forward P/E- EPS next Y-1.38 Insider Trans9.45% Shs Float197.87M Perf Month61.76%
Income-432.98M PEG- EPS next Q-0.44 Inst Own73.23% Short Float / Ratio17.99% / 4.96 Perf Quarter1.79%
Sales0.71M P/S2256.42 EPS this Y24.78% Inst Trans-2.10% Short Interest35.59M Perf Half Y-28.86%
Book/sh2.63 P/B2.38 EPS next Y26.57% ROA-61.93% Target Price20.42 Perf Year-2.19%
Cash/sh1.41 P/C4.43 EPS next 5Y- ROE-81.10% 52W Range3.21 - 9.36 Perf YTD-2.03%
Dividend- P/FCF- EPS past 5Y-11.99% ROI-58.27% 52W High-33.12% Beta0.36
Dividend %- Quick Ratio4.11 Sales past 5Y0.00% Gross Margin-4082.60% 52W Low95.02% ATR0.45
Employees503 Current Ratio4.21 Sales Q/Q- Oper. Margin-63131.40% RSI (14)71.61 Volatility8.38% 8.87%
OptionableYes Debt/Eq0.12 EPS Q/Q26.68% Profit Margin-61241.44% Rel Volume0.89 Prev Close6.07
ShortableYes LT Debt/Eq0.10 EarningsNov 07 AMC Payout- Avg Volume7.18M Price6.26
Recom1.29 SMA2029.80% SMA5044.85% SMA200-0.09% Volume6,373,447 Change3.13%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Buy $12
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Dec-07-21Resumed Cowen Outperform
Nov-20-23 12:00PM
Nov-17-23 05:00PM
Nov-08-23 05:04PM
04:26PM Loading…
Nov-07-23 04:26PM
Oct-31-23 04:01PM
Oct-24-23 06:54AM
Oct-20-23 05:15PM
Oct-16-23 08:15AM
Sep-27-23 04:01PM
Sep-22-23 06:25PM
Sep-15-23 04:20PM
07:26AM Loading…
Sep-14-23 06:10PM
Sep-07-23 11:30AM
Aug-31-23 10:16PM
Aug-28-23 11:53PM
Aug-18-23 05:00PM
Aug-09-23 11:14AM
Aug-08-23 05:50PM
Jul-31-23 06:10AM
Jul-25-23 04:01PM
Jul-24-23 04:01PM
05:34PM Loading…
Jul-21-23 05:34PM
Jul-13-23 04:01PM
Jul-11-23 04:30PM
Jul-10-23 09:46PM
Jun-24-23 03:19PM
Jun-20-23 07:01AM
Jun-16-23 08:39AM
Jun-15-23 07:01AM
Jun-09-23 07:01AM
Jun-08-23 11:30AM
May-30-23 04:18PM
May-29-23 10:08AM
May-26-23 05:30PM
May-24-23 12:03PM
May-16-23 09:25AM
May-11-23 01:40PM
May-10-23 12:16PM
May-09-23 04:01PM
May-02-23 04:01PM
May-01-23 04:00PM
Apr-24-23 07:01AM
Apr-20-23 09:45AM
Apr-06-23 07:22AM
Mar-30-23 11:30AM
Mar-27-23 03:56PM
Mar-24-23 04:01PM
Mar-21-23 05:10PM
Mar-04-23 08:13AM
Mar-02-23 09:17PM
Mar-01-23 12:33PM
Feb-28-23 04:01PM
Feb-27-23 09:31AM
Feb-21-23 04:01PM
Jan-24-23 12:15PM
Jan-23-23 06:37PM
Dec-16-22 09:54AM
Dec-11-22 07:23AM
Nov-30-22 07:00AM
Nov-21-22 12:11PM
Nov-18-22 01:06PM
Nov-12-22 08:34AM
Nov-10-22 12:33PM
Nov-07-22 08:01AM
Nov-04-22 12:31PM
Nov-03-22 04:01PM
Oct-27-22 07:19PM
Oct-24-22 04:01PM
Oct-11-22 11:49AM
Oct-10-22 07:30AM
Oct-05-22 09:45AM
Sep-12-22 07:00AM
Sep-06-22 04:01PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vogt Frederick GInterim CEO & General CounselOct 16Option Exercise0.0020,835093,685Oct 18 08:05 PM
BILINSKY IGORChief Operating OfficerOct 16Option Exercise0.002,813030,026Oct 18 08:04 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerOct 16Option Exercise0.002,813033,766Oct 18 08:03 PM
MCPEAK MERRILL ADirectorSep 18Buy5.5610,00055,600248,633Sep 19 04:30 PM
Rothbaum Wayne P.DirectorSep 15Buy5.305,000,00026,500,00023,067,333Sep 15 06:12 PM
BILINSKY IGORChief Operating OfficerJul 14Option Exercise0.002,813028,608Jul 17 06:21 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 14Option Exercise0.002,813032,348Jul 17 06:22 PM
Vogt Frederick GInterim CEO & General CounselJul 14Option Exercise0.0020,834081,701Jul 17 06:22 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerApr 14Option Exercise0.002,812030,930Apr 18 05:49 PM
Vogt Frederick GInterim CEO & General CounselApr 14Option Exercise0.0020,834069,718Apr 18 05:50 PM
BILINSKY IGORChief Operating OfficerApr 14Option Exercise0.002,812027,190Apr 18 05:48 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 17Option Exercise0.0011,248032,796Jan 19 04:52 PM
BILINSKY IGORChief Operating OfficerJan 17Option Exercise0.0011,248029,049Jan 19 04:52 PM
Vogt Frederick GInterim CEO & General CounselJan 17Option Exercise0.0083,325085,325Jan 19 04:51 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 03Option Exercise0.0019,690032,571Jan 05 08:57 PM
BILINSKY IGORChief Operating OfficerJan 03Option Exercise0.0018,850028,354Jan 05 08:45 PM
Bellemin Jean-MarcChief Financial OfficerJan 03Option Exercise0.0018,850028,354Jan 05 08:45 PM
MCPEAK MERRILL ADirectorDec 21Buy6.1510,00061,50070,150Dec 22 04:06 PM